Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Breyanzi
Biotech
Allogene abandons leukemia CAR-T plans after Breyanzi approval
Allogene has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from the likes of Bristol Myers Squibb.
James Waldron
Nov 14, 2024 5:59am
BMS closes Redwood City cell therapy research site
Apr 26, 2024 10:59am
Medidata study explores CAR-T's cytokine release syndrome risk
Jun 6, 2022 7:10am
Caribou ready to uncork the chardonnay with early phase 1 data
May 12, 2022 10:00am
